Pay in 4 interest-free payments of $6.82 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
Tirzepatide is an investigational once-weekly GIPR/GLP-1R dual agonist 15 with a profound therapeutic superiority in reducing blood glucose and body weight beyond several approved drugs such as semaglutide 16 and dulaglutide 17 in multiple head-to-head clinical trials
The VDR is a member of the steroid and thyroid hormone superfamily of nuclear receptors
In fact, before researchers recognized their powerful weight loss capabilities, these medications originally treated individuals with type 2 diabetes
A 2017 study found this extract exhibited anti-inflammatory effects
Intracerebroventricular (ICV) infusion of native GLP-1 promotes not only a reduction in food intake and body weight, but also an increase in BAT thermogenesis induced by increased sympathetic nervous system (SNS) activity [6]
